Clinical recommendations in the management of advanced prostate cancer: International Gastrointestinal, Liver and Uro-oncology (IGILUC 2019) experts.

Humans Male Prostatic Neoplasms / diagnosis
Advanced prostate cancer Consensus Metastatic prostate cancer Prostate cancer

Journal

World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716

Informations de publication

Date de publication:
May 2021
Historique:
received: 30 12 2019
accepted: 23 06 2020
pubmed: 10 7 2020
medline: 1 10 2021
entrez: 10 7 2020
Statut: ppublish

Résumé

Advancements in the diagnosis and treatment of prostate cancer (PC) have rapidly progressed through the past years. Various factors should be taken into account while treating individual patients to ensure optimal and careful decision making. The purpose of this consensus review is to summarize the current practice patterns when managing patients with advanced prostate cancer (APC) as there is still a lack of or very limited evidence on its clinical management in some areas. Pre-defined questions were shared with experts prior to the consensus session that took place in Cairo, Egypt in April 2019 during the 8th International gastrointestinal, liver and uro-oncology conference (IGILUC). Voting was based mainly on the expert opinions of the panel after a thorough discussion and review of available evidence from guidelines or best evidence available concerning the topic at hand. A strong consensus or unanimity was reached on 47% of the proposed questions. Notably, the panelists reached consensus on several topics based on high-level expert opinion. These findings contribute in several ways to our understanding of the management of PC and provide a basis for future recommendations. There was also a lack of consensus on other several topics, which suggests the need for further supporting data addressing these knowledge gaps. This review offers a thorough understanding of APC practice and offers insight on the various opinions shared amongst experts in the field that can serve as guidance regionally and deepens our understanding of disease management globally.

Identifiants

DOI: 10.1007/s00345-020-03328-3 PMID: 32643031
pubmed: 32643031
doi: 10.1007/s00345-020-03328-3
pii: 10.1007/s00345-020-03328-3
doi:

Types de publication

Journal Article Practice Guideline

Langues

eng

Sous-ensembles de citation

IM

Pagination

1421-1429

Références

Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492
doi: 10.3322/caac.21492
Collaboration GB of DC (2017) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the Global Burden of Disease Study Global Burden. JAMA Oncol 3:524–548. https://doi.org/10.1001/jamaoncol.2016.5688
doi: 10.1001/jamaoncol.2016.5688
Thompson IMJ, Tangen CM, Paradelo J et al (2006) Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 296:2329–2335. https://doi.org/10.1001/jama.296.19.2329
doi: 10.1001/jama.296.19.2329 pubmed: 17105795
Bolla M, van Poppel H, Tombal B et al (2012) Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet (London, England) 380:2018–2027. https://doi.org/10.1016/S0140-6736(12)61253-7
doi: 10.1016/S0140-6736(12)61253-7
Wiegel T, Bottke D, Steiner U et al (2009) Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 27:2924–2930. https://doi.org/10.1200/JCO.2008.18.9563
doi: 10.1200/JCO.2008.18.9563 pubmed: 19433689
Gillessen S, Attard G, Beer TM et al (2018) Management of patients with advanced prostate cancer: the Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol 73:178–211. https://doi.org/10.1016/j.eururo.2017.06.002
doi: 10.1016/j.eururo.2017.06.002 pubmed: 28655541
Parker C, Clarke NW, Cook A, Kynaston HG, Meidahl Petersen P et al (2019) Timing of radiotherapy (RT) after radical prostatectomy (RP): first results from the RADICALS RT randomised controlled trial (RCT) [NCT00541047]. Ann Oncol 30(suppl_5):v851–v934. https://doi.org/10.1093/annonc/mdz394
doi: 10.1093/annonc/mdz394
Touijer KA, Mazzola CR, Sjoberg DD et al (2014) Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy. Eur Urol 65:20–25. https://doi.org/10.1016/j.eururo.2013.03.053
doi: 10.1016/j.eururo.2013.03.053 pubmed: 23619390
Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V et al (2019) EAU guidelines: EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. EAU Guidelines Office, Arnhem
James ND, de Bono JS, Spears MR et al (2017) Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 377:338–351. https://doi.org/10.1056/NEJMoa1702900
doi: 10.1056/NEJMoa1702900 pubmed: 28578639 pmcid: 5533216
Mohler JL, Antonarakis ES, Armstrong AJ et al (2019) Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 17:479–505. https://doi.org/10.6004/jnccn.2019.0023
doi: 10.6004/jnccn.2019.0023 pubmed: 31085757
Li R, Ravizzini GC, Gorin MA et al (2018) The use of PET/CT in prostate cancer. Prostate Cancer Prostatic Dis 21:4–21. https://doi.org/10.1038/s41391-017-0007-8
doi: 10.1038/s41391-017-0007-8 pubmed: 29230009
Schuster DM, Nanni C, Fanti S et al (2014) Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid: physiologic uptake patterns, incidental findings, and variants that may simulate disease. J Nucl Med 55:1986–1992. https://doi.org/10.2967/jnumed.114.143628
doi: 10.2967/jnumed.114.143628 pubmed: 25453047 pmcid: 4844004
Perera M, Papa N, Christidis D et al (2016) Sensitivity, specificity, and predictors of positive (68)Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol 70:926–937. https://doi.org/10.1016/j.eururo.2016.06.021
doi: 10.1016/j.eururo.2016.06.021 pubmed: 27363387
Vag T, Heck MM, Beer AJ et al (2014) Preoperative lymph node staging in patients with primary prostate cancer: comparison and correlation of quantitative imaging parameters in diffusion-weighted imaging and 11C-choline PET/CT. Eur Radiol 24:1821–1826. https://doi.org/10.1007/s00330-014-3240-8
doi: 10.1007/s00330-014-3240-8 pubmed: 24889997
Nanni C, Schiavina R, Rubello D et al (2013) The detection of disease relapse after radical treatment for prostate cancer: is anti-3-18F-FACBC PET/CT a promising option? Nucl Med Commun 34:831–833
doi: 10.1097/MNM.0b013e3283636eaf
Lehmann J, Flesch M, Gedamke M (2019) Quality of life differences for LHRH-antagonist versus LHRH-agonist in special patient groups with cardiovascular comorbidities and higher tumor burden in patients with hormone-sensitive prostate cancer (hsPCa). J Clin Oncol 37:153. https://doi.org/10.1200/JCO.2019.37.7_suppl.153
doi: 10.1200/JCO.2019.37.7_suppl.153
Martín-Merino E, Johansson S, Morris T, Rodríguez LAG (2011) Androgen deprivation therapy and the risk of coronary heart disease and heart failure in patients with prostate cancer. Drug Saf 34:1061–1077. https://doi.org/10.2165/11594540-000000000-00000
doi: 10.2165/11594540-000000000-00000 pubmed: 21981434
Albertsen PC, Klotz L, Tombal B et al (2014) Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol 65:565–573. https://doi.org/10.1016/j.eururo.2013.10.032
doi: 10.1016/j.eururo.2013.10.032 pubmed: 24210090
Rick FG, Block NL, Schally AV (2013) An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer. Onco Targets Ther 6:391–402. https://doi.org/10.2147/OTT.S32426
doi: 10.2147/OTT.S32426 pubmed: 23620672 pmcid: 3633549
Mottet N, Bellmunt J, Bolla M et al (2017) EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 71:618–629. https://doi.org/10.1016/j.eururo.2016.08.003
doi: 10.1016/j.eururo.2016.08.003 pubmed: 27568654
Klotz L, Boccon-Gibod L, Shore ND et al (2008) The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 102:1531–1538. https://doi.org/10.1111/j.1464-410X.2008.08183.x
doi: 10.1111/j.1464-410X.2008.08183.x pubmed: 19035858
Shore ND (2013) Experience with degarelix in the treatment of prostate cancer. Ther Adv Urol 5:11–24. https://doi.org/10.1177/1756287212461048
doi: 10.1177/1756287212461048 pubmed: 23372607 pmcid: 3547532
Sweeney CJ, Chen Y-H, Carducci M et al (2015) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 373:737–746. https://doi.org/10.1056/NEJMoa1503747
doi: 10.1056/NEJMoa1503747 pubmed: 26244877 pmcid: 4562797
Gravis G, Fizazi K, Joly F et al (2013) Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 14:149–158. https://doi.org/10.1016/S1470-2045(12)70560-0
doi: 10.1016/S1470-2045(12)70560-0 pubmed: 23306100
Chi KN, Agarwal N, Bjartell A et al (2019) Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med 381:13–24. https://doi.org/10.1056/NEJMoa1903307
doi: 10.1056/NEJMoa1903307 pubmed: 31150574
Clarke NW, Ali A, Ingleby FC et al (2019) Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Ann Oncol Off J Eur Soc Med Oncol. https://doi.org/10.1093/annonc/mdz396
doi: 10.1093/annonc/mdz396
Davis ID, Martin AJ, Stockler MR et al (2019) Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med 381:121–131. https://doi.org/10.1056/NEJMoa1903835
doi: 10.1056/NEJMoa1903835 pubmed: 31157964
Hoyle AP, Ali A, James ND et al (2019) Abiraterone in “High-” and “Low-risk” metastatic hormone-sensitive prostate cancer. Eur Urol. https://doi.org/10.1016/j.eururo.2019.08.006
doi: 10.1016/j.eururo.2019.08.006 pubmed: 31447077
Parker CC, James ND, Brawley CD et al (2018) Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet (London, England) 392:2353–2366. https://doi.org/10.1016/S0140-6736(18)32486-3
doi: 10.1016/S0140-6736(18)32486-3
Boeve LMS, Hulshof MCCM, Vis AN et al (2019) Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a Prospective Randomised Clinical Trial. Eur Urol 75:410–418. https://doi.org/10.1016/j.eururo.2018.09.008
doi: 10.1016/j.eururo.2018.09.008 pubmed: 30266309
Fischer S, Gillessen S, Sydes MR, Omlin AG (2018) Differences in treatment recommendations for advanced prostate cancer according to region and medical specialization: analysis of the APCCC 2017 voting results. Ann Oncol 29(suppl_8):viii271-viii302. https://doi.org/10.1093/annonc/mdy284
Scher HI, Graf RP, Schreiber NA et al (2018) Assessment of the validity of nuclear-localized androgen receptor splice variant 7 in circulating tumor cells as a predictive biomarker for castration-resistant prostate cancer assessment of validity of AR-V7 in tumor cells as a predictive biomarker for Ca. JAMA Oncol 4:1179–1186. https://doi.org/10.1001/jamaoncol.2018.1621
doi: 10.1001/jamaoncol.2018.1621 pubmed: 29955787 pmcid: 6139066
Antonarakis ES, Lu C, Wang H et al (2014) AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371:1028–1038. https://doi.org/10.1056/NEJMoa1315815
doi: 10.1056/NEJMoa1315815 pubmed: 25184630 pmcid: 4201502
Berthold DR, Pond GR, Soban F et al (2008) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 26:242–245. https://doi.org/10.1200/JCO.2007.12.4008
doi: 10.1200/JCO.2007.12.4008 pubmed: 18182665
de Bono JS, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet (London, England) 376:1147–1154. https://doi.org/10.1016/S0140-6736(10)61389-X
doi: 10.1016/S0140-6736(10)61389-X
Fizazi K, Tran N, Fein L et al (2017) Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 377:352–360. https://doi.org/10.1056/NEJMoa1704174
doi: 10.1056/NEJMoa1704174 pubmed: 28578607
Beer TM, Armstrong AJ, Rathkopf DE et al (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371:424–433. https://doi.org/10.1056/NEJMoa1405095
doi: 10.1056/NEJMoa1405095 pubmed: 24881730 pmcid: 4418931
Karantanos T, Karanika S, Gignac G (2016) Uncontrolled diabetes predicts poor response to novel antiandrogens. Endocr Relat Cancer 23:691–698. https://doi.org/10.1530/ERC-16-0222
doi: 10.1530/ERC-16-0222 pubmed: 27515296
Szmulewitz RZ, Peer CJ, Ibraheem A et al (2018) Prospective international randomized phase II study of low-dose abiraterone with food versus standard dose abiraterone in castration-resistant prostate cancer. J Clin Oncol 36:1389–1395. https://doi.org/10.1200/JCO.2017.76.4381
doi: 10.1200/JCO.2017.76.4381 pubmed: 29590007 pmcid: 5941614

Auteurs

Hesham Elghazaly (H)

Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt. heshamelghazaly@hotmail.com.

Nicolas Mottet (N)

Department of Urology, University Hospital Nord St. Etienne, St. Etienne, France.

Jorge Garcia (J)

Department of Solid Tumor Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.

Stephane Oudard (S)

Department of Medical Oncology, Georges Pompidou European Hospital, Paris, France.

Mack Roach (M)

Department of Radiation Oncology, University of California, San Francisco, CA, USA.

Claude Abbou (C)

Department of Urology, Hôpital Henri Mondor, Creteil, France.

Axel Merseburger (A)

Department of Urology and Urologic Oncology, Campus Lübeck, University Hospital Schleswig-Holstein, Lübeck, Germany.

Amr Emara (A)

Department of Urology, Hampshire Hospitals, NHS Foundation Trust, Basingstoke, UK.

Samir Shehata (S)

Clinical Oncology Department, Assiut University Cancer Centre, Assiut, Egypt.

Hesham Tawfik (H)

Clinical Oncology Department, Tanta University, Tanta, Egypt.

Ola Khorshid (O)

Medical Oncology Department National Cancer Institute, Cairo University, Cairo, Egypt.

Ahmed Selim (A)

Clinical Oncology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.

Akram Assem (A)

Urology Department, Alexandria University, Alexandria, Egypt.

Khalid Abdelkarim (K)

Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

Lobna Ezz El-Arab (L)

Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

Shouki Bazarbashi (S)

Medical Oncology Department, King Faisal Specialist Hospital and Research Center, Riyadh, Kingdom of Saudi Arabia.

Abbass Omar (A)

Department of Clinical Oncology, Faculty of Medicine, Alexandria University, Alexandria, Egypt.

Hesham Elwakil (H)

Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

Mohamed Elashry (M)

Department of Clinical Oncology, Faculty of Medicine, Mansoura University, Mansoura, Egypt.

Mohamed Abou ElFotouh (M)

Department of Clinical Oncology, Faculty of Medicine, Menoufia University, Al Minufya, Egypt.

Tarek Osman (T)

Department of Urology, Ain Shams University, Cairo, Egypt.

Mai Ezz El Din (M)

Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Clinical recommendations in the management of...
questionsmedicales.fr › Maladies urogénitales › Tumeurs de l'appareil urogénital › Tumeurs de l'appareil génital mâle › Tumeurs de la prostate › Clinical recommendations in the management of...